Alnylam Announces Manufacturing Agreement with DowpharmaSM for RNAi Therapeutics

04-Apr-2005

Alnylam Pharmaceuticals, Inc. and DowpharmaSM, a business unit of The Dow Chemical Company announced an agreement for the manufacture and supply of candidate RNAi therapeutics for Alnylam's lead development programs in age-related macular degeneration (AMD) and respiratory syncytial virus (RSV) infection. Dowpharma will manufacture short interfering RNAs (siRNAs), the molecules that induce RNAi, for use in clinical trials.

"This agreement is an important step in our transition to a clinical-stage company as we rapidly advance multiple RNAi therapeutic candidates into human trials," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "Dowpharma is a high-quality partner who will provide Alnylam access to large-scale synthesis and purification of siRNAs necessary for clinical development."

The Dowpharma contract service agreement will provide Alnylam with large quantities of GMP-certified siRNAs necessary for near-term toxicology and clinical studies on RNAi therapeutic candidates. Dowpharma will manufacture siRNAs for use in certain Alnylam programs, including those in AMD and RSV.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances